Seminars in Oncology
Volume 31, Issue 1 , Pages 83-89 , February 2004

The role of monoclonal antibodies in stem cell transplantation

  • Tarun Wasil

      Affiliations

    • Long Island Jewish Medical Center, Division of Hematology-Oncology, New Hyde Park, NY, USA
    • Albert Einstein College of Medicine, Bronx, NY, USA
    • Corresponding Author InformationAddress reprint requests to Tarun Wasil, MBBS, Attending Physician, Long Island Jewish Medical Center, 270-05 76th Ave, New Hyde Park, NY, 11040, USA
    • ,
  • Kanti R Rai

      Affiliations

    • Long Island Jewish Medical Center, Division of Hematology-Oncology, New Hyde Park, NY, USA
    • Albert Einstein College of Medicine, Bronx, NY, USA
    • ,
  • Bhoomi Mehrotra

      Affiliations

    • Long Island Jewish Medical Center, Division of Hematology-Oncology, New Hyde Park, NY, USA
    • Albert Einstein College of Medicine, Bronx, NY, USA

References 

  1. Rohatiner AZ, Johnson PW, Price CG, et al.  Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol. 1994;12:1177–1184
  2. Bierman PJ, Armitage JO. Non-Hodgkin’s lymphoma. Curr Opin Hematol. 1996;3:266–272
  3. Gribben JG, Freedman AS, Neuberg D, et al.  Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325:1525–1533
  4. Freedman AS, Neuberg D, Mauch P, et al.  Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325–3333
  5. Ball ED, Mills LE, Cornell GG, et al.  Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody-purged bone marrow. Blood. 1990;75:1199–1206
  6. Soiffer RJ, Roy DC, Fonin R, et al.  Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant. 1993;12:243–251
  7. Granena A, Castellsague X, Badel I, et al.  Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia (Clinical relevance of ex-vivo bone marrow purging with monoclonal antibodies and complement). Bone Marrow Transplant. 1999;24:621–627
  8. Reff ME, Carner K, Chambers KS, et al.  Depletion of B cells in vivo by chimeric mouse-human monoclonal antibody to CD20. Blood. 1994;83:435–445
  9. Buckstein R, Imrie K, Spaner D, et al.  Stem-cell function and engraftment is not affected by “in vivo purging” with rituximab for autologous stem-cell treatment for patients with low-grade non-Hodgkin’s lymphoma. Semin Oncol. 1999;26(suppl 14):115–122
  10. Voso MT, Pantel G, Weis M, et al.  In vivo depletion of B-cells using a combination of high dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin’s lymphoma. Br J Haematol. 2000;109:729–735
  11. Kosmas C, Stamalopoulos K, Stavroyianni N, et al.  Anti-CD20-based therapy of B-cell lymphoma (state of the art). Leukemia. 2002;16:2004–2015
  12. Flinn IW, O’Donnell PV, Goodrich A, et al.  Immunotherapy with rituximab during peripheral blood stem-cells transplantation for non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2000;6:628–632
  13. Magni M, DiNicole M, Devizzi L, et al.  Successful in vivo purging of CD3 containing peripheral blood harvests in mantle cell and indolent lymphoma (Evidence for a role of both chemotherapy and rituximab infusion). Blood. 2000;96:864–869
  14. Ladetto M, Zallio F, Vallet S, et al.  Concurrent administration of high dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin’s lymphoma. Leukemia. 2001;15:1941–1949
  15. Papadaki T, Stamatopoulos K, Stavroyianni N, et al.  Evidence for T-large granular lymphocyte mediated neutropenia in rituximab-treated lymphoma patients (Report of two cases). Leuk Res. 2002;26:597–600
  16. Horwitz S, Negrin R, Stockerl-Goldstein K, et al.  Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem-cell transplantation for relapsed refractory non-Hodgkin’s lymphomas. Blood. 2002;98:862a; (suppl 1, abstr 3578)
  17. Buckstein R, Imrie K, Spaner D, et al.  Autologous stem-cell transplants combined with rituximab for relapsed follicular lymphoma achieves prolonged clinical and molecular remissions. Blood. 2001;98:68a; (suppl 2, abstr 2846)
  18. Mangel J, Buckstein R, Imrie K, et al.  Immunotherapy with rituximab following high dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol. 2002;29(suppl 2):56–69
  19. Gisselbrecht C. In vivo purging and relapse prevention following ASCT. Bone Marrow Transplant. 2002;29(suppl 1):S5–S9
  20. Waldmann H, Polliack A, Hale G, et al.  Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1H). Lancet. 1984;2:483–486
  21. Slavin S, Waldmann H, Or R, et al.  Prevention of graft-vs-host disease in allogeneic transplantation for leukemia by T-cell depletion in vitro prior to transplantation. Transplant Proc. 1985;17:465–467
  22. Cobbold SP, Martin G, Qin S, et al.  Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature. 1986;323:164–166
  23. Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant. 1994;13:597–611
  24. Reichmann L, Clarke M, Waldmann H, et al.  Reshaping human antibodies for therapy. Nature. 1988;332:323–327
  25. Clarke E, Potter MN, Oakhill A, et al.  A laboratory comparison of T cell depletion by CD34 cell immunoaffinity selection and in-vitro Campath-1M treatment (Clinical implications for bone marrow transplantation and donor leukocyte therapy). Bone Marrow Transplant. 1997;20:599–605
  26. Ginaldi L, De Martinis M, Matutes E, et al.  Levels of expression of CD52 in normal and leukemic B and T cells (Correlation with in-vivo therapeutic responses to Campath-1H). Leuk Res. 1998;22:185–191
  27. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in-vitro. Blood. 1993;82:807–812
  28. Cull GM, Haynes AP, Byrne JL, et al.  Preliminary experience of allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning (An effective regimen with low procedure-related mortality). Br J Haematol. 2000;108:754–776
  29. Lush RJ, Haynes AP, Byrne JL, et al.  Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/−fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy. 2001;3:203–210
  30. Hale G, Zhang MJ, Bunjes D, et al.  Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 1998;92:4581–4590
  31. Hale G, Jacobs P, Wood L, et al.  CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem-cells. Bone Marrow Transplant. 2000;26:69–76
  32. Giralt S, Estey E, Albitar M, et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy (Harnessing graft-versus-leukemia without myeloablative therapy). Blood. 1997;89:4531–4536
  33. Slavin S, Nagler A, Naparstek E, et al.  Nonmyeloablative stem-cell transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  34. Khouri IF, Keating M, Korbling M, et al.  Transplant-lite (induction of graft-versus-maignancy using fludarabine based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies). J Clin Oncol. 1998;16:2817–2824
  35. Nagler A, Slavin S, Varadi G, et al.  Allogeneic peripheral blood stem-cell transplantation using fludarabine-based low intensity regimen for malignant lymphoma. Bone Marrow Transplant. 2000;25:1021–1028
  36. Kottaridis PD, Milligan DW, Chopra R, et al.  In-vivo CAMPATH-1H prevents GVHD following nonmyeloablative stem-cell transplantation. Cytotherapy. 2001;3:197–201
  37. Kottaridis PD, Milligan DW, Chopra R, et al.  In-vivo Campath-1H prevents GVHD following nonmyeloablative stem-cell transplantation. Blood. 2000;96:2419–2425
  38. Chakrabarti S, Mackinnon S, Chopra R, et al.  High incidence of cytomegalovirus infection after nonmyeloablative stem-cell transplantation (Potential role of Campath-1H in delaying immune reconstitution). Blood. 2002;99:4357–4363
  39. Perez-Simon JA, Kottaridis PD, Martino R, et al.  Nonmyeloablative transplantation with or without alemtuzumab (Comparison between 2 prospective studies in patients with lymphoproliferative disorders). Blood. 2002;100:3121–3127
  40. Curtis RE, Travis LE, Rowlings PA, et al.  Risk of lymphoproliferative disorders after bone marrow transplantation (A multiinstitutional study). Blood. 1999;94:2208–2216
  41. Micallef IN, Channabhai N, Gascoyne RD, et al.  Lymphoproliferative disorders following allogeneic bone marrow transplantation (The Vancouver experience). Bone Marrow Transplant. 1998;22:981–987
  42. Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH users. Blood. 1998;91:3079–3083
  43. Dyer MJS, Kelsey SM, Mackay HJ, et al.  In vivo purging of residual disease in CLL with Campath-1H. Br J Haematol. 1997;97:669–672
  44. Kennedy SM, Rawstron AC, Evans P, et al.  Campath-1H therapy in 29 patients with refractory CLL (“True” complete remission is an attainable goal). Blood. 1999;94:603a; (abstr)

PII: S0093-7754(03)00567-0

doi: 10.1053/j.seminoncol.2003.11.005

Seminars in Oncology
Volume 31, Issue 1 , Pages 83-89 , February 2004

Article Tools